<DOC>
	<DOCNO>NCT00437606</DOCNO>
	<brief_summary>This study investigate effect hepatic impairment pharmacokinetics , pharmacodynamics , safety tolerability GK Activator ( 2 ) type 2 diabetes patient mild moderate hepatic impairment . Patients type 2 diabetes , normal hepatic function , mild moderate hepatic impairment , receive single dose GK Activator ( 2 ) 100mg po breakfast , assessment pharmacokinetic , pharmacodynamic safety parameter . The anticipated time study treatment &lt; 3 month , target sample size &lt; 100 individual .</brief_summary>
	<brief_title>A Study Pharmacokinetics/Pharmacodynamics GK Activator ( 2 ) Type 2 Diabetes Patients With Hepatic Impairment .</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Ethanol</mesh_term>
	<criteria>adult patient , 1875 year age ; type 2 diabetes ; normal hepatic function , mild moderate hepatic impairment . type 1 diabetes , latent autoimmune diabetes adult ; diabetic neuropathy , retinopathy nephropathy ; treatment insulin PPAR gamma agonist within 6 week screen ; clinically significant cardiovascular disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>